AU2000255635A1 - A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one - Google Patents

A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one

Info

Publication number
AU2000255635A1
AU2000255635A1 AU2000255635A AU5563500A AU2000255635A1 AU 2000255635 A1 AU2000255635 A1 AU 2000255635A1 AU 2000255635 A AU2000255635 A AU 2000255635A AU 5563500 A AU5563500 A AU 5563500A AU 2000255635 A1 AU2000255635 A1 AU 2000255635A1
Authority
AU
Australia
Prior art keywords
pyrimidin
methyl
tetrahydro
preparation
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000255635A
Inventor
Tarur Venkatasubramanian Radhakrishnan
Dhananjay Govind Sathe
Chandrakant Vasantrao Suryavanshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RPG Life Sciences Ltd
Original Assignee
RPG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RPG Life Sciences Ltd filed Critical RPG Life Sciences Ltd
Publication of AU2000255635A1 publication Critical patent/AU2000255635A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for the preparation of 3-substituted ethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one of the formula IIB: where X may be halo, acyloxy, or sulfonyloxy such as tosyloxy or mesyloxy, an intermediate in the synthesis of the anti-psychotic risperidone. The process comprises hydrogenation of 3-substituted ethyl-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one in aqueous inorganic acid medium at atmospheric to 60 psi at 0-100° C. in the presence of a metal catalyst and the product is isolated. A process for the preparation of risperidone of the formula I: comprising condensation of 3-substituted ethyl-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one with 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole in water in the presence of an inorganic base at 25-100° C. and the product is isolated.
AU2000255635A 2000-05-05 2000-05-05 A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one Abandoned AU2000255635A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2000/000053 WO2001085731A1 (en) 2000-05-05 2000-05-05 A PROCESS FOR THE PREPARATION OF ANTI-PSCHOTIC 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one

Publications (1)

Publication Number Publication Date
AU2000255635A1 true AU2000255635A1 (en) 2001-11-20

Family

ID=11076248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000255635A Abandoned AU2000255635A1 (en) 2000-05-05 2000-05-05 A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one

Country Status (7)

Country Link
US (1) US6897308B1 (en)
EP (1) EP1280804B1 (en)
AT (1) ATE264329T1 (en)
AU (1) AU2000255635A1 (en)
CZ (1) CZ295402B6 (en)
DE (1) DE60009959T2 (en)
WO (1) WO2001085731A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982980A1 (en) 2000-08-14 2008-10-22 Teva Pharmaceutical Industries Ltd. Crystalline form of risperidone
HU227118B1 (en) * 2001-11-13 2010-07-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one
ES2197801B1 (en) * 2002-03-05 2005-03-16 Ferrer Internacional,S.A PROCEDURE FOR OBTAINING THE 3- (2- (4- (6-FLUORO-BENZO (D) ISOXAZOL-3-IL) PIPERIDIN-1-IL) -ETIL) -2-METHYL-6,7,8,9- TETRAHIDRO-4H-PIRIDO- (1,2-A) PIRIMIDIN-4-ONA.
KR20040025224A (en) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-3-yl)acetaldehyde and preparation process of the same
KR20040034996A (en) * 2002-10-18 2004-04-29 한미약품 주식회사 Improved method for the preparation of risperidone
EP1560814A1 (en) 2002-11-13 2005-08-10 Synthon B.V. Process for making risperidone and intermediates therefor
ZA200603113B (en) * 2003-09-26 2007-08-29 Jubilant Organosys Ltd Process for the preparation of risperidone
HUP0401379A3 (en) * 2004-07-08 2006-04-28 Richter Gedeon Vegyeszet Process for the preparation of risperidon
HUP0402163A2 (en) * 2004-10-25 2006-05-29 Richter Gedeon Vegyeszet Process for the preparation of risperidone
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007093870A2 (en) * 2006-02-15 2007-08-23 Orchid Chemicals & Pharmaceuticals Limited A process for the preparation of risperidone
WO2008021345A2 (en) * 2006-08-14 2008-02-21 Teva Pharmaceutical Industries Ltd. Process for the synthesis of 9-hydroxy risperidone (paliperidone)
US7820816B2 (en) * 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
BRPI0811319A2 (en) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc FLUID COMPOSITION, METHOD FOR FORMATION OF A FLUID COMPOSITION, BIODEGRADABLE IMPLANT FORMED IN SITU, METHOD FOR FORMATION OF A BIODEGRADABLE IMPLANT, KIT, IMPLANT AND TREATMENT METHOD
CN101353347B (en) * 2007-07-26 2011-06-01 齐鲁制药有限公司 Preparation of risperidone
EP2285804A4 (en) * 2008-04-21 2011-09-14 Glenmark Generics Ltd A process for the preparation of paliperidone intermediates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355037A (en) 1981-11-12 1982-10-19 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidyl)-1,2-benzisoxales
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5015740A (en) 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4957916A (en) * 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
ES2050069B1 (en) * 1992-07-10 1994-12-16 Vita Invest Sa PROCEDURE FOR OBTAINING 3- (2- (4- (6-FLUORO-1,2-BENZISOXAZOL-3-IL) PIPERIDINO) ETIL) -2-METHYL-6,7,8,9-TETRAHIDRO-4H-PIRIDO (1,2-A) PIRIMIDIN-4-ONA.
ES2074966B1 (en) * 1994-02-11 1996-06-16 Vita Invest Sa PROCEDURE FOR OBTAINING 3- (2- (4- (6-FLUORO-BENZO (D) ISOXAZOL-3-IL) PIPERIDIN-1-IL) -ETIL) -2-METHYL-6,7,8,9- TETRAHIDRO-4H-PIRIDO- (1,2-A) PIRIMIDIN-4-ONA.

Also Published As

Publication number Publication date
CZ20023666A3 (en) 2003-02-12
CZ295402B6 (en) 2005-08-17
ATE264329T1 (en) 2004-04-15
EP1280804A1 (en) 2003-02-05
DE60009959T2 (en) 2005-03-31
WO2001085731A1 (en) 2001-11-15
US6897308B1 (en) 2005-05-24
DE60009959D1 (en) 2004-05-19
EP1280804B1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
AU2000255635A1 (en) A process for the preparation of anti-pschotic 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl -6,7,8,9-tetrahydro-2-methyl-4h-pyridol(1,2,-a)pyrimidin-4- one
US7071198B1 (en) Substituted pyrazoles as p38 kinase inhibitors
ES2373672T3 (en) PIRROLO DERIVATIVES [2,3-C] PIRIDINE AND PROCESSES FOR PREPARATION.
US9145410B2 (en) Pyrazolopyridines and analogs thereof
US7544697B2 (en) Pyrazolopyridines and analogs thereof
US20110195954A1 (en) Novel compounds
EP0588858B1 (en) IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE
US8686143B2 (en) Compounds useful as inhibitors of Janus kinases
TW200305420A (en) Compounds useful in therapy
IE900069L (en) 2-aminopyrimidinone derivatives
JP2004504397A5 (en)
US20120157440A1 (en) Novel fused pyridine compounds as casein kinase inhibitors
MXPA05005814A (en) Pyrazole and imidazole compounds and uses thereof.
TW201125864A (en) Novel compounds as casein kinase inhibitors
EP1749004A1 (en) Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
JPS63301879A (en) Novel 1-alkyl substituted benzimidazole derivative
NZ540495A (en) 1,3-Dihydro-imidazole fused-ring compound
AU619877B2 (en) Antipsychotic 3-piperazinyl benzazole, benzisoxazole and benzisothiazole derivatives
IE912533A1 (en) Novel substituted thiazolyl and substituted pyridinyl¹derivatives
WO2009044413A3 (en) Improved process for preparing paliperidone, novel polymorphic forms of the same and process thereof
EP0808313B1 (en) Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives
EP0295742B1 (en) Novel n-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
WO2006005974A8 (en) A process for the preparation of risperidone
ES2050069A1 (en) Prepn of anti-psychotic pyrimidinone - which is 3-(2-(4-(6-fluoro- 1,2-benzisoxazol 3-yl)piperidino) ethyl)-2-methyl- 6,7,8,9-tetra- hydro-4H-pyrido (1,2-a) pyrimidin-4-one
EP0393738A1 (en) Hydroxyalkylfuranyl derivatives